Nektar Therapeutics Share Price Today
(NASDAQ: NKTR)

Name: Nektar Therapeutics Share Price Today (NASDAQ: NKTR) - Nektar Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Nektar Therapeutics share price is $0.86 & ₹74.79 as on 6 Mar 2025, 2.30 'hrs' IST

$0.86

▲

0.01

(1.67%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Nektar Therapeutics share price in Dollar and Rupees. Guide to invest in Nektar Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Nektar Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Nektar Therapeutics share price movements

Today's Low: $0.84
Today's High: $0.88
$0.86
2.33%
Downside
Day's Volatility :4.4%
Upside
2.13%
52 Weeks Low: $0.65
52 Weeks High: $1.93
$0.86
24.42%
Downside
52 Weeks Volatility :66.29%
Upside
55.39%

Nektar Therapeutics (NKTR) Returns

Period	Nektar Therapeutics	Sector (Health Care)	Index (Russel 2000)
3 Months	-17.27%	2.1%	0.0%
6 Months	-25.33%	-4.1%	0.0%
1 Year	-7.26%	2.2%	0.0%
3 Years	-91.66%	11.8%	-11.6%

Nektar Therapeutics (NKTR) Key Statistics

in dollars & INR

Previous Close	$0.8438
Open	$0.85
Today's High	$0.8787
Today's Low	$0.84
Market Capitalization	$147.9M
Today's Volume	$427.5K
52 Week High	$1.928
52 Week Low	$0.65
Revenue TTM	$93.1M
EBITDA	$-130.2M
Earnings Per Share (EPS)	$-0.84
Profit Margin	-180.7%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-161.63%

How to invest in Nektar Therapeutics Stock (NKTR) from India?

It is very easy for Indian residents to invest directly in Nektar Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Nektar Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Nektar Therapeutics or NKTR on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Nektar Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Nektar Therapeutics shares which would translate to 1.011 fractional shares of Nektar Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Nektar Therapeutics, in just a few clicks!

Returns in Nektar Therapeutics (NKTR) for Indian investors in Rupees

The Nektar Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Nektar Therapeutics investment value today

Current value as on today

₹99,468

Returns

₹532

(-0.53%)

Returns from Nektar Therapeutics Stock

₹5,495 (-5.49%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Nektar Therapeutics (NKTR)

12%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Nektar Therapeutics Stock from India on INDmoney has increased by 12% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Nektar Therapeutics

BlackRock Inc
8.72%
Vanguard Group Inc
6.68%
Samlyn Capital, LLC
5.24%
Nantahala Capital Management, LLC
4.23%
Eventide Asset Management, LLC
3.61%
PRIMECAP Management Company
3.00%

Analyst Recommendation on Nektar Therapeutics

Hold

0%Buy

55%Hold

44%Sell

Based on 9 Wall street analysts offering stock ratings for Nektar Therapeutics(by analysts ranked 0 to 5 stars)

Based on 9 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Nektar Therapeutics Stock (NKTR)

What analysts predicted

Upside of 430.23%

Target:

$4.56

Current:

$0.86

Insights on Nektar Therapeutics Stock (Ticker Symbol: NKTR)

Price Movement
In the last 7 days, NKTR stock has moved up by 8.2%
Increasing Revenue
Revenue is up for the last 3 quarters, 21.63M → 24.12M (in $), with an average increase of 5.3% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -52.36M → -37.05M (in $), with an average increase of 41.3% per quarter
NKTR vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 66.9%
NKTR vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 139.7%
Price to Sales
ForNKTR every $1 of sales, investors are willing to pay $1.8, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

NKTR Nektar Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$1.2B	↑ 287.81%
Net Income	$681.3M	↓ 804.62%
Net Profit Margin	57.09%	↑ 88.51%

	FY19	Y/Y Change
Revenue	$114.6M	↓ 90.4%
Net Income	$-440.7M	↓ 164.68%
Net Profit Margin	-384.47%	↓ 441.56%

	FY20	Y/Y Change
Revenue	$152.9M	↑ 33.41%
Net Income	$-444.4M	↑ 0.86%
Net Profit Margin	-290.65%	↑ 93.82%

	FY21	Y/Y Change
Revenue	$101.9M	↓ 33.36%
Net Income	$-523.8M	↑ 17.86%
Net Profit Margin	-514.03%	↓ 223.38%

	FY22	Y/Y Change
Revenue	$92.1M	↓ 9.67%
Net Income	$-368.2M	↓ 29.71%
Net Profit Margin	-399.98%	↑ 114.05%

	FY23	Y/Y Change
Revenue	$90.1M	↓ 2.1%
Net Income	$-276.1M	↓ 25.03%
Net Profit Margin	-306.31%	↑ 93.67%

	Q2 FY23	Q/Q Change
Revenue	$20.5M	↓ 5.07%
Net Income	$-51.1M	↓ 62.69%
Net Profit Margin	-249.39%	↑ 385.13%

	Q3 FY23	Q/Q Change
Revenue	$24.1M	↑ 17.78%
Net Income	$-45.8M	↓ 10.34%
Net Profit Margin	-189.85%	↑ 59.54%

	Q4 FY23	Q/Q Change
Revenue	$23.9M	↓ 1.07%
Net Income	$-42.1M	↓ 8.2%
Net Profit Margin	-176.17%	↑ 13.68%

	Q1 FY24	Q/Q Change
Revenue	$21.6M	↓ 9.4%
Net Income	$-36.8M	↓ 12.54%
Net Profit Margin	-170.07%	↑ 6.1%

	Q2 FY24	Q/Q Change
Revenue	$23.5M	↑ 8.55%
Net Income	$-52.4M	↑ 42.28%
Net Profit Margin	-222.93%	↓ 52.86%

	Q3 FY24	Q/Q Change
Revenue	$24.1M	↑ 2.7%
Net Income	$-37.1M	↓ 29.23%
Net Profit Margin	-153.61%	↑ 69.32%

	FY18	Y/Y Change
Profit	$1.2B	↑ 321.74%

	FY19	Y/Y Change
Profit	$93.2M	↓ 92.02%

	FY20	Y/Y Change
Profit	$133.4M	↑ 43.11%

	FY21	Y/Y Change
Profit	$77.0M	↓ 42.29%

	FY22	Y/Y Change
Profit	$70.4M	↓ 8.56%

	FY23	Y/Y Change
Profit	$53.5M	↓ 24.06%

	Q2 FY23	Q/Q Change
Profit	$13.5M	↓ 7.08%

	Q3 FY23	Q/Q Change
Profit	$11.7M	↓ 13.27%

	Q4 FY23	Q/Q Change
Profit	$16.6M	↑ 41.74%

	Q1 FY24	Q/Q Change
Profit	$13.1M	↓ 21.06%

	Q2 FY24	Q/Q Change
Profit	$13.7M	↑ 4.91%

	Q3 FY24	Q/Q Change
Profit	$19.7M	↑ 43.2%

	FY18	Y/Y Change
Operating Cash Flow	$718.2M	↓ 993.15%
Investing Cash Flow	$-1.4B	↑ 4689.95%
Financing Cash Flow	$852.0M	↑ 1466.37%

	FY19	Y/Y Change
Operating Cash Flow	$-328.7M	↓ 145.76%
Investing Cash Flow	$206.9M	↓ 114.99%
Financing Cash Flow	$23.4M	↓ 97.26%

	FY20	Y/Y Change
Operating Cash Flow	$-313.3M	↓ 4.68%
Investing Cash Flow	$496.2M	↑ 139.85%
Financing Cash Flow	$-80.4M	↓ 444.05%

	FY21	Y/Y Change
Operating Cash Flow	$-412.7M	↑ 31.72%
Investing Cash Flow	$202.8M	↓ 59.14%
Financing Cash Flow	$36.2M	↓ 145.1%

	FY22	Y/Y Change
Operating Cash Flow	$-304.0M	↓ 26.33%
Investing Cash Flow	$365.8M	↑ 80.41%
Financing Cash Flow	$1.5M	↓ 95.84%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-51.5M	↓ 0.76%
Investing Cash Flow	$25.2M	↓ 38.0%
Financing Cash Flow	$18.0K	↑ 0.0%

Nektar Therapeutics Technicals Summary

Sell

Neutral

Buy

Nektar Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Nektar Therapeutics (NKTR) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Nektar Therapeutics	4.31%	-25.33%	-7.26%	-91.66%	-95.24%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Nektar Therapeutics	NA	NA	3.22	-0.8	-1.62	-0.23	NA	0.27
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Nektar Therapeutics	Hold	$147.9M	-95.24%	NA	-180.7%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. The company serves its clients in the United States and internationally. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Organization	Nektar Therapeutics
Employees	137
CEO	Mr. Howard W. Robin
Industry	Health Technology

Management People of Nektar Therapeutics

Name	Title
Mr. Howard W. Robin	CEO, President & Director
Ms. Sandra A. Gardiner	Chief Financial Officer
Mr. Mark A. Wilson J.D.	Senior VP, Chief Legal Officer & Secretary
Dr. Jonathan Zalevsky Ph.D.	Chief Research & Development Officer
Mr. Jason Barnard	Chief Accounting Officer
Ms. Vivian Wu	Director of Investor Relations & Corporate Affairs
Mr. Robert Bacci	Chief People Officer and Head of Quality & Facilities
Ms. Jennifer Ruddock	Chief Business Officer
Dr. Brian L. Kotzin M.D.	Interim Chief Medical Officer

Important FAQs about investing in NKTR Stock from India :

What is Nektar Therapeutics share price today?

Nektar Therapeutics share price today stands at $0.86, Open: $0.85 ; Previous Close: $0.84 ; High: $0.88 ; Low: $0.84 ; 52 Week High: $1.93 ; 52 Week Low: $0.65.

The stock opens at $0.85, after a previous close of $0.84. The stock reached a daily high of $0.88 and a low of $0.84, with a 52-week high of $1.93 and a 52-week low of $0.65.

Can Indians buy Nektar Therapeutics shares?

Yes, Indians can invest in the Nektar Therapeutics (NKTR) from India.

With INDmoney, you can buy Nektar Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Nektar Therapeutics at zero transaction cost.

How can I buy Nektar Therapeutics shares from India?

It is very easy to buy Nektar Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Nektar Therapeutics (NKTR) be purchased?

Yes, you can buy fractional shares of Nektar Therapeutics with INDmoney app.

What are the documents required to start investing in Nektar Therapeutics stocks?

To start investing in Nektar Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.